Related Experiment Video
Updated: Aug 16, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
MDM4: What do we know about the association between its polymorphisms and cancer?
Gabriela Mattevi Almeida1, Ana Clara Castilho1, Douglas Adamoski1,2
1Post-Graduation Program in Genetics, Department of Genetics, Federal University of Parana, Curitiba, PR, 81530-900, Brazil.
Abstract:
MDM4 is an important p53-negative regulator, consequently, it is involved in cell proliferation, DNA repair, and apoptosis regulation. MDM4 overexpression and amplification are described to lead to cancer formation, metastasis, and poor disease prognosis. Several MDM4 SNPs are in non-coding regions, and some affect the MDM4 regulation by disrupting the micro RNA binding site in 3'UTR (untranslated region). Here, we gathered several association studies with different MDM4 SNPs and populations to understand the relationship between its SNPs and solid tumor risk. Many studies failed to replicate their results regarding different populations, cancer types, and risk genotypes, leading to conflicting conclusions. We suggested that distinct haplotype patterns in different populations might affect the association between MDM4 SNPs and cancer risk. Thus, we propose to investigate some linkage SNPs in specific haplotypes to provide informative MDM4 markers for association studies with cancer.
Insights
The MDM4 gene, a key regulator of cell processes, has single nucleotide polymorphisms (SNPs) linked to cancer risk. Investigating specific MDM4 SNP haplotypes may clarify their association with solid tumor development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- MDM4 is a crucial negative regulator of p53, impacting cell proliferation, DNA repair, and apoptosis.
- MDM4 overexpression/amplification is associated with cancer formation, metastasis, and poor prognosis.
- MDM4 single nucleotide polymorphisms (SNPs) in non-coding regions can affect gene regulation by altering microRNA binding sites in the 3'UTR.
Purpose of the Study:
- To synthesize findings from various association studies on MDM4 SNPs and solid tumor risk across different populations.
- To address conflicting conclusions arising from inconsistent replication of results in prior research.
- To propose a refined approach for investigating MDM4 SNPs in relation to cancer risk.
Main Methods:
- Compilation and analysis of existing association studies examining MDM4 SNPs and solid tumor risk.
- Evaluation of study discrepancies related to population, cancer type, and risk genotypes.
- Hypothesizing the role of population-specific haplotype patterns in modulating SNP-cancer associations.
Main Results:
- Numerous studies reported inconsistent findings regarding the association between MDM4 SNPs and cancer risk.
- Replication failures were common across different populations, cancer types, and identified risk genotypes.
- Conflicting conclusions highlight the complexity of SNP-cancer associations.
Conclusions:
- Distinct haplotype patterns within different populations likely influence the observed associations between MDM4 SNPs and cancer risk.
- Investigating linked SNPs within specific haplotypes is recommended for developing more informative MDM4 markers.
- This approach could enhance the power and reliability of future association studies for cancer risk prediction.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Related Concept Videos
Abnormal Proliferation
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Cancers Originate from Somatic Mutations in a Single Cell
Inhibition of Cdk Activity
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Master Transcription Regulators